INS and lipodystrophy: For these reasons, the clinician should inspect the insulin injection/infusion sites regularly to identify lipodystrophy (lipohypertrophy and/or lipoatrophy), especially in patients with erratic glycemic control, so measures to manage the problem and prevent the development of further areas of lipoatrophy can be implemented.